PMV Pharmaceuticals Inc. Common Stock (PMVP)
Stock · NASDAQ · Health Care
$1.21as of 10/16/2026
Price chart
Active signals
PMVP Signal Track Record
How signals performed across all stocks →What PMVP's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 45 | -2.1% | 33% | September 30, 2026 |
| Bollinger Band Breakdown | 27 | 0.0% | 48% | July 28, 2026 |
| Bollinger Band Breakout | 18 | -7.8% | 33% | September 30, 2026 |
| 200-Day Moving Average TouchActive now | 17 | -4.2% | 29% | September 2, 2026 |
| Any 20-session window (baseline) | -3.1% | 40% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About PMVP
PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule therapies targeting p53 mutations and other p53-related cancers in the United States. It develops rezatapopt, a selective structural corrector of p53 Y220C mutations in Phase 2 clinical trials for tumor agnostic diseases. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 54
- Website
- www.pmvpharma.com/
Fundamentals
- 1-day range
- $1.23$1.3
- Market cap
- $62.93M
- P/E (trailing)
- —
- P/E (forward)
- -1.28
- EPS (trailing)
- $-1.41
- Dividend yield
- —
- Beta
- 1.48
- Avg. volume
- 659.3K
Forecasts
5 analyst ratings
PMV Pharmaceuticals Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- PMVPPMV Pharmaceuticals Inc. Common Stock$1.21▼ 6.20%Market cap $62.93MP/E —$1.02$1.91
- BOLDBoundless Bio Inc. Common Stock$2.34▼ 0.43%Market cap $63.80MP/E —$0.9612$3.16
- ANVSAnnovis Bio Inc. Common Stock$0.99▼ 5.71%Market cap $64.44MP/E —$1.01$5.5
- PLRXPliant Therapeutics Inc. Common Stock$0.9▼ 7.41%Market cap $65.02MP/E —$0.8838$1.95
- HYFTMindWalk Holdings Corp. Common Stock$1.31▼ 6.43%Market cap $59.79MP/E —$0.99$2.99
- MNOVMedicinova Inc Common Stock$1.42▼ 2.07%Market cap $66.94MP/E —$1.17$3.9
- DWTXDogwood Therapeutics Inc. Common Stock$1.22▼ 2.40%Market cap $58.85MP/E —$1.24$7.04
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| PMVP PMV Pharmaceuticals Inc. Common Stock | $62.93M | — | $1.21 | ▼ 6.20% | $1.02$1.91 |
| BOLD Boundless Bio Inc. Common Stock | $63.80M | — | $2.34 | ▼ 0.43% | $0.9612$3.16 |
| ANVS Annovis Bio Inc. Common Stock | $64.44M | — | $0.99 | ▼ 5.71% | $1.01$5.5 |
| PLRX Pliant Therapeutics Inc. Common Stock | $65.02M | — | $0.9 | ▼ 7.41% | $0.8838$1.95 |
| HYFT MindWalk Holdings Corp. Common Stock | $59.79M | — | $1.31 | ▼ 6.43% | $0.99$2.99 |
| MNOV Medicinova Inc Common Stock | $66.94M | — | $1.42 | ▼ 2.07% | $1.17$3.9 |
| DWTX Dogwood Therapeutics Inc. Common Stock | $58.85M | — | $1.22 | ▼ 2.40% | $1.24$7.04 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- PMV Pharmaceuticals: Restoring Mutant P53 Could Create A Mispriced Cancer OpportunitySeekingAlpha · 10/7/2026
- PMV Pharmaceuticals Appoints Matt Eckler, Ph.D., to Board of DirectorsYahoo · 10/5/2026
- These Biotech Stocks Are Cheap Based On 1 Fundamental MeasureYahoo · 9/17/2026
- Should You Buy PMV Pharmaceuticals, Inc. (PMVP) After Golden Cross?Yahoo · 9/16/2026
Insider Activity
Insider Actions →- Eckler Matthew Joseph · October 1, 2026 · Grant84.0K
- Stelzer Laurie · June 4, 2026 · Grant42.0K
- Charles M. Baum · June 4, 2026 · Grant42.0K
- FLOWERS KIRSTEN · June 4, 2026 · Grant42.0K
- Carol Giltner Gallagher · June 4, 2026 · Gift42.0K
- Carol Giltner Gallagher · June 4, 2026 · Grant42.0K
- LEVINE ARNOLD J · June 4, 2026 · Grant42.0K
Institutional Ownership
March 31, 2026
- Total shares held
- 36.73M
- Total value held
- $42.71M
- Institutional holders
- 66
- Unknown5.32M
- Unknown4.25M
- Unknown3.08M
- Unknown2.87M
- Unknown2.63M
- Unknown2.35M
- Unknown2.22M
- Unknown1.97M
- Unknown1.88M
- Unknown1.86M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 6, 2026
PMV Pharmaceuticals Adds Matt Eckler to Board
PMV Pharmaceuticals has appointed Matt Eckler, Ph.D., to its Board of Directors. This corporate update adds to the company's leadership team. The stock is currently trading near the top of its 52-week range, with an RSI of 69.0 indicating strong recent momentum.
PMV Pharmaceuticals Adds Matt Eckler to Board. PMV Pharmaceuticals has appointed Matt Eckler, Ph.D., to its Board of Directors. This corporate update adds to the company's leadership team. The stock is currently trading near the top of its 52-week range, with an RSI of 69.0 indicating strong recent momentum.